0.690
-0.30 (-30.48%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Skye Bioscience, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 价值 35% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 35% | -0.3 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -0.5 |
| 技术平均移动指标 参考 | 0.0 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -17.9% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | 2.6 |
| 最终评分 | -0.13 |
|
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.44% |
| 机构持股比例 | 80.76% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Platinum Investment Management Ltd | 30 Jun 2026 | 29,137 |
该时间范围内无数据。
该时间范围内无数据。
投资组合